Pharming Group/$PHAR

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About Pharming Group

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Ticker

$PHAR
Primary listing

Industry

Biotechnology

Employees

404

ISIN

US71716E1055

Pharming Group Metrics

BasicAdvanced
$742M
-
-$0.02
0.44
-

Bulls say / Bears say

Pharming Group reported a 42% increase in total revenues to $79.1 million in Q1 2025, with RUCONEST® revenue growing by 49% to $68.6 million and Joenja® revenue rising by 9% to $10.5 million, indicating strong product performance. (stocktitan.net)
Analysts from Jefferies Financial Group initiated coverage on Pharming Group with a 'buy' rating and a $14.00 price target, reflecting confidence in the company's growth prospects. (defenseworld.net)
Pharming Group received a positive recommendation from NICE for Joenja® as a treatment for APDS, facilitating its reimbursement within the NHS and potentially expanding its market reach. (stockanalysis.com)
Pharming Group's net margin stands at -1.64%, indicating ongoing profitability challenges despite revenue growth. (benzinga.com)
The company's return on equity (ROE) is -0.57%, suggesting inefficiencies in generating returns from shareholder equity. (benzinga.com)
Pharming Group's return on assets (ROA) is -0.28%, reflecting challenges in effectively utilizing its assets to generate profits. (benzinga.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PHAR

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs